Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Eculizumab reduces relapse-related hospitalizations in patients with NMOSD

Publish date:: February 29, 2020

Key clinical point: Eculizumab reduces relapse-related hospitalizations and associated treatment in patients with NMOSD.

Major finding: The annualized relapse-related hospitalization rate was lower in the eculizumab group (0.04) than in the placebo group (0.31).

Study details: A randomized, double-blind, placebo-controlled study of 143 patients with NMOSD.

Disclosures: Alexion Pharmaceuticals, which markets eculizumab, sponsored the study. Dr. Wingerchuk received grants from Alexion during the study.

Kim H et al. ACTRIMS 2020.

Citation:

Abstract P197

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,